GH replacement therapy in GH-deficient adults has recently been shown to increase (normalize) muscle volume and decrease adipose tissue volume as measured by means of CT scan and skinfold thickness. Also in adults with acquired GH deficiency in adulthood, GH replacement has been shown to significantly influence body composition with an increase in lean body mass and a reduction in skinfold thickness. Preliminary results from an open long-term trial indicate that 12 months of GH substitution result in a further normalization of the muscle/fat ratio. The fluid-retaining effect, with a significant increase in extracellular-fluid volume demonstrated during GH administration to normal subjects, seems to be of little clinical importance if a replacement dose around 2 IU/m2/day is chosen for young GH-deficient adults. Long-term trials are needed to finally establish the indication of GH replacement therapy in GH-deficient adults.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000181586 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human Growth Hormone (GH) use by Athletes with Short Stature without GH Deficiency: Therapeutic Use Exemptions.
J Clin Endocrinol Metab
January 2025
Division of Diabetes and Endocrinology, Department of Pediatrics, University of Virginia, Charlottesville, VA.
Organized sports are governed by specific rules which aim to create or preserve fair play. An unfair advantage can be obtained by the use of specific substances or methods, also referred to as doping. The World Anti-Doping Agency (WADA) leads the international doping-free sport movement and annually publishes the List of Prohibited Substances and Methods (List), that is used by most sport federations and organizations around the world.
View Article and Find Full Text PDFImpact of non-weight-dependent low-dose somatropin on bone accrual in childhood-onset GH deficient in the transition: an 18-month randomized controlled trial.
J Pediatr (Rio J)
January 2025
Faculdade de Medicina da Universidade de São Paulo (FMUSP), Instituto da Criança, Unidade de Endocrinologia Pediátrica, São Paulo, São Paulo, Brazil.
Objective: Discontinuation of growth hormone therapy (rhGH) upon completion of linear growth may adversely affect bone mineral density and content (BMD/BMC) in adolescents with childhood-onset GH deficiency (CO-GHD) and predisposition to osteoporosis. Although the benefits of weight-dependent somatropin high doses over bone gain are established, little is known about fixed low doses. We analyzed the impact of non-weight-based low-dose somatropin on bone accrual during the transition among CO-DGH patients, treated since childhood.
View Article and Find Full Text PDFPitfalls of diagnosing pituitary hypoplasia in the patients with short stature.
Endocrine
October 2024
Division of Pediatric Endocrinology and Metabolism, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.
Purpose: Height age (HA) and bone age (BA) delay is well known in the patients with short stature. Therefore assessing pituitary hypoplasia based on chronological age (CA) might cause overdiagnosis of pituitary hypoplasia. We aimed to investigate the diagnostic and prognostic value of the PH and PV based on CA, HA, or BA in the patients with GHD.
View Article and Find Full Text PDFExploring height outcomes with adjuvant aromatase inhibition in growth hormone-deficient male survivors of childhood cancer.
Pediatr Blood Cancer
August 2024
Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Background: Aromatase inhibitors (AI) may improve height in short stature conditions; however, the effect in childhood cancer survivors (CCS) is unknown. We assessed final adult height (FAH) in CCS treated with AI and GH compared with those treated with GH alone.
Methods: Retrospective cohort study of GH-deficient male CCS treated between 2007 and 2023.
Evaluation of growth hormone deficiency in women with unexplained infertility.
Growth Horm IGF Res
February 2024
Memorial Kayseri Hospital, Department of Endocrinology, Kayseri, Turkey.
Purpose: Growth hormone (GH) has been recognized to play a regulatory role in female reproduction. It has been reported that infertile GH deficient patients regained fertility after GH replacement. The frequency of GH deficiency is not established in patients diagnosed with unexplained infertility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!